Public Hearing - December 5, 2017

 

Public Hearing on Fentanyl, Fentanyl Analogues, and Synthetic Cannabinoids

Washington, DC

Tuesday, December 5, 2017 at 9:00 a.m.

 

Notice

Pursuant to Rule 3.4 of the Rules of Practice and Procedure of the United States Sentencing Commission, a public hearing is scheduled for Tuesday, December 5, 2017, at 9:00 a.m. (ET).

The public hearing will be held at the Thurgood Marshall Federal Judiciary Building, One Columbus Circle, N.E., Washington, DC in Suite 2-500 (South Lobby).  The hearing was streamed live.  

The purpose of the public hearing is for the Commission to receive testimony from experts on fentanyl, fentanyl analogues, and synthetic cannabinoids, including their chemical structure, pharmacological effects, trafficking patterns, and community impact.

Chair's Remarks
Transcript
Public Hearing - December 5, 2017
Read More

Fentanyl & Fentanyl Analogues

Panel I
Law Enforcement
9:00 a.m. – 9:40 a.m.

Robert Perez
Acting Executive Assistant Commissioner
Operations Support
U.S. Customs & Border Protection

Joe Schleigh
Acting Chief
Synthetic Drugs and Chemicals Section
Diversion Control Division (Special Agent)
U.S. Drug Enforcement Administration

Major Juan Colon
New Jersey State Police
Office of the Attorney General
New Jersey Office of Drug Addiction Control

Panel II
Structural Chemistry & Pharmacology
9:40 a.m. – 10:05 a.m.

Dr. Michael Van Linn
Drug Science Specialist/Chemist
Drug and Chemical Evaluation Section
Diversion Control Division
U.S. Drug Enforcement Administration

Dr. Srihari Tella
Unit Chief, Pharmacologist
Drug and Chemical Evaluation Section
Diversion Control Division
U.S. Drug Enforcement Administration

Barry K. Logan, Ph.D., F-ABFT
NMS Labs
Senior Vice President of Forensic Science Initiatives
Chief of Forensic Toxicology
Willow Grove, Pennsylvania

Panel III
First Responders & Health Consequences
10:15 a.m. – 10:40 a.m.

Dr. Brian J. Browne
Chair, Department of Emergency Medicine Section
University of Maryland
School of Medicine
Baltimore, Maryland

Dr. Roger A. Mitchell
Chief Medical Examiner
Office of Chief Medical Examiner
Washington, DC

Dr. Howard Haft
Deputy Secretary for Public Health
Maryland Department of Health and Mental Hygiene
Baltimore, Maryland

Break
10:40 a.m. – 10:55 a.m.

Synthetic Cannabinoids

Panel IV
Law Enforcement
10:55 a.m. – 11:10 a.m.

Joe Schleigh
Acting Chief
Synthetic Drugs and Chemicals Section
Diversion Control Division (Special Agent)
U.S. Drug Enforcement Administration

Panel V
Definition, Structural Chemistry, & Pharmacology
11:10 a.m. – 11:35 a.m.

Dr. Jordan Trecki
Pharmacologist
Drug and Chemical Evaluation Section
Diversion Control Division
U.S. Drug Enforcement Administration

Dr. Daniel Willenbring
Drug Science Specialist/Chemistry
Drug and Chemical Evaluation Section
Diversion Control Division
U.S. Drug Enforcement Administration

Michael Gatch, Ph.D.
Associate Professor – Biomedical Sciences
University of North Texas
Fort Worth, Texas

Panel VI
Community Impact
11:35 a.m. – 12:00 p.m.

Matthew Barber
Detective
Lubbock Police Department
Street Crimes/SWAT
Lubbock, Texas

Chad Curry
Training Chief
University Medical Center Emergency Medical Services (UMC EMS)
Lubbock, Texas

Gerad Troutman, MD, MBA, FACEP
EMS Medical Director
University Medical Center Emergency Medical Services (UMC EMS)
President Elect of the Texas College of Emergency Physicians
Co-Founder and CEO of ER Now
Amarillo, Texas

Adjourn
12:00 p.m.

To receive updates on future events and other Commission activities, visit us on Twitter or subscribe to our e-mail listserve in the website footer below. For questions regarding this notice, e-mail our Public Affairs Office at pubaffairs@ussc.gov or call us at (202) 502‐4500.